Wealth Advisory Solutions LLC Decreases Position in Johnson & Johnson (NYSE:JNJ)

Wealth Advisory Solutions LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 30.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,092 shares of the company’s stock after selling 2,610 shares during the quarter. Wealth Advisory Solutions LLC’s holdings in Johnson & Johnson were worth $881,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Crew Capital Management Ltd. raised its holdings in shares of Johnson & Johnson by 2.5% in the fourth quarter. Crew Capital Management Ltd. now owns 5,106 shares of the company’s stock worth $738,000 after buying an additional 126 shares during the period. Mainstream Capital Management LLC bought a new position in Johnson & Johnson in the fourth quarter worth approximately $63,000. Ring Mountain Capital LLC bought a new position in Johnson & Johnson in the fourth quarter worth approximately $318,000. Exencial Wealth Advisors LLC grew its stake in Johnson & Johnson by 2.3% in the fourth quarter. Exencial Wealth Advisors LLC now owns 44,573 shares of the company’s stock worth $6,446,000 after purchasing an additional 1,000 shares in the last quarter. Finally, AMJ Financial Wealth Management grew its stake in Johnson & Johnson by 508.2% in the fourth quarter. AMJ Financial Wealth Management now owns 6,806 shares of the company’s stock worth $160,000 after purchasing an additional 5,687 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.1 %

Johnson & Johnson stock opened at $165.22 on Thursday. The stock has a market capitalization of $397.79 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The business has a fifty day moving average price of $152.11 and a 200-day moving average price of $156.19. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $2.29 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.00%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

JNJ has been the topic of several research analyst reports. Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Raymond James dropped their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Leerink Partners dropped their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Finally, Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.